Content Detail

• Content META

  Title	Soligenix to Present at Upcoming Investor Conferences
  ID	5946011
  External ID	7471498622
  Author	Unknown
  Published Date	Jan. 16, 2025, 8:02 a.m.
  Summary	Share this Story PRINCETON, N.J. Jan. 16, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commerc
  Tags	press-release
  URL	https://www.pinoybisnes.com/press/soligenix-to-present-at-upcoming-investor-conferences/
  Sentiment	Negative: 0.01144    Neutral: 0.91255    Positive: 0.07601
  Relevance	0.00714

• Content Details

  Content ID	3623942
  Key	3f190fed-9a72-4ea5-b689-d0f077027a6f
  Content	Share this Story PRINCETON, N.J. Jan. 16, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. close Advertisements PinoyBisnes arrow_forward_ios Read More CANCEL NEXT VIDEO Pause Play % buffered Unmute Mute Play Powered by GliaStudio Sequire Investor Summit, held January 21 to 23 at Condado Vanderbilt, Puerto Rico . For more information about the Sequire Investor Summit, please refer to the conference website at https://puertorico.srax.com/ The Microcap Conference, held January 28 to 30 at Borgata Hotel Casino & Spa in Atlantic City, N.J. For more information about The Microcap Conference, please refer to the conference website at https://themicrocapconference.com Key members of Soligenix management will hold one-on-one meetings throughout these conferences. Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platforms. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected] About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease. Our Public Health Solutions business segment includes development programs for RiVax ® , our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax ® . To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “hopes,” “intends,” “plans,” “expects,” “goal,” “may,” “suggest,” “will,” “potential,” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax ® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax ® . Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. SOURCE SOLIGENIX, INC. These Might Interest You: HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma Clinical Trial Outsourcing Market Expected To Reach USD 111.01 Billion by 2032, Growing at a CAGR of 8.7% From 2024-2032 | Introspective Market Research Clinical Trials Market in the US to grow by USD 5 Billion from 2024-2028, driven by more drug trials, with AI redefining market trends – Technavio eClinical Solutions Market to Grow by USD 12.77 Billion (2024-2028), Rising Drug Clinical Trials Drive Revenue, Report Highlights AI Impact on Trends – Technavio Immunic Highlights 2024 Accomplishments and Upcoming Milestones Post navigation JETOUR Speeds Ahead: Record-Breaking Sales with 80.3% Growth in 2024 Infosys: Strong growth of 6.1% YoY in CC, 80 bps YoY operating margin expansion
  Content Reference URL	None

• Publisher

  Publisher Name	Pinoy bisnes Ideas (#1720)
  Publisher URL	https://www.pinoybisnes.com/
  Description	None
  Trust Flow Score	3
  Citation Flow Score	23

• Data Source

  Data Source Name	Quantexa News (#5)
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10